Realistic Lead Times for Cells, Tissue and Custom Devices

The short answer: catalogue cells are one to three weeks, living tissue models are one to six weeks and locked to the supplier’s weekly production cadence, and anything custom is a multi-week programme rather than a delivery date. Contract expansion and differentiation run four to eight weeks per phase, and custom microfabrication runs weeks to months because you are queueing for cleanroom time behind other people’s jobs.

The useful part is not the numbers. It is knowing which of them are hard constraints you cannot buy your way past, and which are soft numbers that stretch. A supplier’s weekly ship day is a hard constraint. A differentiation protocol’s biology is a hard constraint. A “typical” lead time on a disease-mutant line is not a constraint at all — it is a statement about a lot that may or may not exist.

The master table

These are the lead times we record against each offering we broker, with what moves them. They are planning ranges for research-grade material with paperwork already cleared.

Category	Item	Typical lead time	What drives the variance	What makes it longer
Cells	Human iPSC-derived cortical neurons	1–3 weeks from order, subject to lot availability	Whether the supplier holds a released lot of your subtype and genotype	Reporter lines (GFP, GCaMP), non-standard donor constraints, media kit out of stock separately from cells
Cells	Human iPSC-derived spinal motor neurons	1–4 weeks; disease-mutant lines longer if no lot in inventory	Genotype. Normal lines behave like stock; mutant lines are lumpy	ALS patient and SOD1 A4V lines; requiring a matched isogenic control that is stocked and priced separately
Cells	Human iPSC-derived neural stem cells / NPCs	1–3 weeks	Straightforward stock item at most suppliers	Donor-lineage restrictions that force a substitution mid-order
Cells	Human iPSC-derived astrocytes	1–3 weeks	Stock item	Being ordered from a different vendor than your neurons, which adds a second shipment and a second paperwork chain
Cells	Human iPSC-derived cardiomyocytes	1–3 weeks	Stock item; subtype (ventricular vs atrial) rarely changes it	Large multi-vial orders that exhaust a lot and force a mixed-lot shipment
Cells	Human skeletal myoblasts (iPSC-derived)	1–3 weeks for catalogue vials	Catalogue vials ship like any other cell SKU	Primary human myoblasts and any GMP-grade production — quote-dependent, and a different order of magnitude
Cells	Human iPSC lines (undifferentiated)	2–6 weeks including MTA execution	The MTA, not the cells. Institutional legal review is the schedule	Commercial-use scope in the MTA; a depositing laboratory that must approve; a line listed but not currently available for purchase
Tissue models	Reconstructed human epidermis (RhE)	1–3 weeks, constrained to the supplier’s weekly Monday production and shipping cadence	The production calendar. Not your order date	Non-standard media variant (phenol-red-free, antibiotic-free, hydrocortisone-free) — these are scheduled production runs, not picking decisions
Tissue models	Reconstructed human airway epithelium	1–4 weeks against the production calendar	Air–liquid-interface culture time is fixed; you are booking a slot	Donor-specific or diseased-donor tissue; large kit counts that span two production lots
Tissue models	Human intestinal epithelial tissue and barrier models	2–5 weeks against supplier production schedules	Longer differentiation than epidermis, same calendar logic	Crypt or organoid-derived formats; anything requiring a specific donor
Tissue models	Ready-to-use liver microtissues and spheroids	2–6 weeks, gated by the supplier’s published production schedule	Published production schedule — some vendors publish theirs, which is a gift	Pooled-donor lots that only run periodically; plate counts that exceed a scheduled run
Tissue models	Pre-seeded perfused organ-on-chip plates	3–8 weeks, quote-dependent	Seeding, perfusion and QC are done for you, which is why it takes longer than empty plates	Custom cell source; anything outside the vendor’s standard tissue menu
Contractile tissue	Engineered skeletal muscle tissue built to spec	Quote-dependent; a multi-week programme, not a shipped consumable	Whether tooling exists, whether the cell input is on hand, how many casts are needed to yield the passing count	New mould geometry; a force acceptance criterion the supplier has not hit before; a first article you did not order separately
Contractile tissue	Neuromuscular junction co-culture model	Quote-dependent; typically several weeks of co-culture after cell delivery	Co-culture maturation biology, downstream of two cell orders	Sourcing motor neurons and myoblasts from different suppliers with incompatible media
Neural interface	MEA-ready neural cultures (plated, matured, delivered active)	Quote-dependent; maturation alone is multi-week after cell delivery	Maturation to network activity. Published MEA data show synchronised signal from day 12 for glutamatergic neurons and around day 18 for motor and mixed cortical	Requiring an activity acceptance criterion at delivery; astrocyte co-culture sourcing; shipping a live plate rather than a frozen vial
Devices	Custom microfluidic and culture device fabrication	Quote-dependent; design iteration plus tooling plus production, weeks to months	Cleanroom queue, plus how many design revisions you need	Feature sizes near the process floor; high aspect ratios; a design you revise after tooling has started
Devices	3D skeletal muscle casting devices and plates	1–4 weeks for stocked devices	Whether the device is stocked or made to order	Microplate-format variants, which are quote-dependent rather than stocked
Devices	Stimulation and contractile readout hardware	Quote-dependent; capital equipment procurement cycles apply	Your own institution’s capital process, usually more than the vendor’s	Tender requirements, capital committee cycles, installation and training scheduling
Native tissue	Native animal tissue collected to specification	1–4 weeks; custom collections gated by abattoir scheduling	The collection calendar at the source facility	Specific anatomical sites, specific ages, or a species that is not routinely processed
Native tissue	Human biospecimens and primary tissue	2 weeks from banked inventory; considerably longer for prospective collection	Banked versus prospective. These are entirely different timescales	Prospective collection against a disease-state or demographic specification, plus IRB and consent scope
Contract culture	Contract cell expansion, banking and cryopreservation	4–8 weeks typical, based on published vendor phase durations	Target cell mass, doubling time and the number of passages required	GMP grade; a bank that must be released against a full test panel; incoming material QC on your cells before they will start
Contract culture	Contract differentiation to a target cell type	4–8 weeks for differentiation alone; longer with editing or 3D formation	The protocol’s own biology. See below	Gene editing upstream; 3D tissue formation downstream; a process that must be developed rather than run
QC	Sterility, mycoplasma, endotoxin, identity and viability panel	1–4 weeks depending on assay	Incubation periods impose hard minimums. Compendial sterility cannot be accelerated	A full release panel where the longest assay sets the date; a repeat needed after an out-of-specification result
QC	Histology, imaging and digital pathology characterisation	2–6 weeks depending on panel complexity	Number of stains, sections and analysis endpoints	Multiplexed immunofluorescence panels; 3D imaging; bespoke image analysis that has to be written
QC	Contractile force and electrophysiology phenotyping	3–5 weeks for a typical study per published vendor phase duration	Number of tissues and conditions	Anything requiring the tissue to be cultured and matured on the vendor’s instrument before recording
Logistics	Cold chain and cryogenic shipping	Booked alongside the goods; live tissue is constrained to the supplier’s weekly ship day	The ship day, not the courier	International lanes, import permits, customs inspection, and any destination where you cannot guarantee someone is present to receive

The six things that actually set your date

1. Lot availability, not production capacity

For catalogue cells the question is almost never “can they make it”. It is “do they have a released lot of exactly this genotype right now”. A normal, non-disease line is effectively a stock item. A disease-mutant or reporter line is a periodic production run, and a line can be listed on a website, priced, and orderable while the next lot is months out.

This asymmetry is invisible on the product page. Two SKUs sitting next to each other at similar prices can be one week and three months apart, and the only way to find out is to ask before you raise the purchase order.

Two practical consequences. Reserve the lot rather than assuming the listing implies stock. And if you need a mutant line and its matched isogenic control, order both at the same time — they are stocked and priced separately, and buyers routinely end up holding a mutant with no control.

2. Inventory versus produce-to-order

The single most useful question to ask any supplier is: do you ship this from inventory, or do you start it when I order?

Inventory suppliers can compress. Produce-to-order suppliers cannot, because the biology sets the floor. And a third category catches people out: suppliers who hold inventory of the cells but produce the media kit to order, or vice versa. A cells-only order can ship in three days while the matched supplement kit takes three weeks, and you have a vial you cannot use.

Ask about every line item on the quote, not just the headline one.

3. Cold-chain scheduling windows

This is the constraint people underestimate most, and it is entirely real.

MatTek’s published technical specification for EpiDerm states that living tissue is shipped at 4°C on medium-supplemented agarose gels, dispatched every Monday, delivered Tuesday morning by priority courier in the US, with a four-day shelf life that includes transit. Thursday dispatch is possible on request. International delivery lands Tuesday to Thursday.

Read what that means for planning:

Your assay window is set by the supplier’s calendar before you book anyone’s time.
Ordering on a Tuesday does not save you a week. It costs you one.
A four-day shelf life including transit means an international shipment arriving Thursday leaves you roughly a day of usable tissue, not four.
Nobody can accelerate this. There is no expedite fee that makes a Monday production run happen on a Wednesday.

Other living-tissue suppliers publish production schedules for the same reason. When a vendor publishes a production calendar, that is not marketing — it is the single most useful planning artifact they produce, and you should ask for it before you ask for a price.

The corollary applies to receiving. Do not accept a Friday delivery of temperature-sensitive material into a building nobody enters until Monday. Suppliers will generally hold to a requested ship date and almost never offer it unprompted.

4. Differentiation biology

If you are buying a differentiation service rather than a vial, the protocol route decides the schedule, and the routes differ by more than an order of magnitude.

Route	Published timing	What this means for a delivery date
NGN2 transcription-factor induction	Induced neuronal cells “clearly identifiable already on day 6”; functional readouts typically at two to three weeks	Fast. A differentiation campaign can realistically sit inside a four-to-eight-week contract window
Dual-SMAD developmental cortical protocol	An 80-day, three-stage process recapitulating cortical development	Roughly twelve weeks of culture before anything ships. This cannot be compressed and is not a scheduling failure when it happens
Maturation to network activity on MEA	Synchronised signal from around day 12 for cortical glutamatergic neurons, around day 18 for spinal motor and mixed cortical neurons; activity sustained at least two weeks after	Add two to four weeks after plating before a culture is worth recording from

The practical error is buying a frozen vial when what the experiment needed was a matured culture, and then discovering the maturation weeks were yours all along. That time is real whether you pay someone else for it or absorb it in your own incubator. The only question is whose risk it is.

5. Cleanroom queue for microfabrication

Custom device fabrication is quote-dependent for a reason that has nothing to do with difficulty. It is a queue.

A custom PDMS or microfluidic build has four serial stages — design, tooling, production, and inspection — and only one of them is proportional to your order size. Design iteration is driven by how many revisions you need, tooling is a fixed block of cleanroom and machine time regardless of whether you order two parts or two hundred, production scales with quantity, and inspection scales with tolerance.

Three things stretch it:

Revisions after tooling has started. The most expensive week in the schedule.
Feature sizes near the bottom of the process capability. Yield falls, inspection rises, and re-runs happen.
Being a small job. A one-off prototype competes for the same cleanroom slot as a production run, and it is not always the one that wins.

If your geometry requirement is soft, ask whether a stock device is close enough. Adapting your fixture to an existing device removes the entire tooling stage from the schedule, and it is frequently the largest single difference between two quotes for what looks like the same object.

6. Customs, import permits and institutional paperwork

The lead times in the table above assume paperwork is already in place. Frequently it is not, and the paperwork chain runs longer than the production chain.

Four items, all of which can run in parallel with production if you start them early and none of which can be compressed once you are waiting:

Import permits. The importer’s responsibility, and the importer’s lead time. Biological material crossing a border needs the permit before it ships, not when it lands.
Institutional MTA review. For iPSC lines this is usually the dominant term — which is why we record two to six weeks for a product that is physically sitting in a freezer.
Biosafety approval for the containment level the material requires.
Purchase order routing, which in a large institution is not instantaneous.

None of these are the supplier’s problem, and none of them appear on the quote. Start them at specification time, not at order time.

Why your quote said six weeks and it took eleven

This is the most common schedule failure in this market, and it is nearly always the same five weeks. Here is where they go.

Where the time went	Typical slip	Why it was not in the quote
The quote was a production estimate, not a delivery estimate	+1 to 2 weeks	The vendor quoted the time to make it. Release testing, packing, cold-chain booking and transit were assumed by you and unstated by them
The clock started at purchase order, not at quote	+1 to 3 weeks	Your own approval, PO routing and MTA review ran before the vendor’s clock started. The vendor’s six weeks were honest; they just began later than you counted from
The lot was not there	+2 to 8 weeks	“Typical lead time” described the normal line. You ordered the mutant. Nobody re-checked availability against your specific genotype at quote time
A dependency shipped separately	+1 to 3 weeks	Media, supplement or coating was a separate line item with its own lead time, and the shortest path was set by the slowest component
The weekly cadence	+0 to 1 week, sometimes twice	Production finished Tuesday. The ship day is Monday. That happens at every hand-off, not once
QC came back out of specification	+1 to 4 weeks	Nobody plans for a re-run, but re-runs happen. On a produce-to-order item this is a full repeat of the production step, not a re-test
Customs, permit or a failed delivery attempt	+3 days to 3 weeks	The permit was applied for after the goods were ready. Or nobody was on site to sign for a live shipment

Five weeks of slip is four of these happening at once, none of them individually unreasonable.

How to stop it happening

Ask for the lead time broken down by phase — tooling, cell expansion, differentiation, maturation, casting, QC, release, packing, transit — rather than as a single number. A supplier who has scheduled the job already holds these figures, so asking costs them nothing.

A phase breakdown does four things at once. It tells you where the schedule risk actually sits. It exposes whether release testing and transit are inside or outside the quoted number. It lets you compare two quotes that both say “six weeks” and discover that one of them means something completely different. And it gives you something to track against, so a slip surfaces in week two rather than week nine.

Then add five specific questions:

Does your clock start at purchase order or at quote acceptance?
Is this lead time from inventory, or do you start production on receipt of the order?
Do you have a released lot of this exact genotype today, and will you reserve it?
What is your ship day, and does the quoted lead time include transit?
What are the separate lead times for the media, supplement and coating line items?

Every one of those is answerable in a sentence by a supplier who knows their own process, and the ones who cannot answer them are telling you something useful too.

Realistic planning, by purchase type

If you are buying	Plan for	And start this now
Catalogue cells, normal line	2–3 weeks	Nothing special. Confirm the media kit ships with the cells
Catalogue cells, disease or reporter line	4–8 weeks, or ask and be told 12	Availability check and lot reservation, before the PO
An iPSC line	4–8 weeks	MTA review. It is the whole lead time
Living tissue model, standard format	2–4 weeks	Ask for the production calendar and pick a delivery week, not a delivery date
Living tissue model, custom media variant	4–6 weeks	Confirm whether your variant is a scheduled run or a stocked item
Contract differentiation	8–14 weeks	The protocol route conversation. NGN2 and dual-SMAD are not the same project
A matured, delivered-active culture	10–16 weeks	Agree the activity acceptance criterion before anything is quoted
Custom device fabrication, first order	8–16 weeks	Freeze the design. Ask whether a stock device is close enough
Custom device fabrication, repeat order	3–6 weeks	Confirm the tooling exists and who owns it
Anything crossing a border	Add 2–4 weeks	The import permit, today

What we would do differently

Two habits are worth more than any amount of expediting.

Order the long-lead item first, separately. If a project needs a custom device and cells, the device sets the date and the cells are a two-week item you can order later against a known delivery week. Ordering both at once means the cells sit in your freezer while you wait, and their clock — passage, warranty window, claim window — is already running.

Buy the first article separately and early. For anything custom, a two-unit first article ordered ahead of the production run finds the specification disagreements while they are still cheap. It costs a few weeks at the front and routinely saves more than that at the back, because the alternative is discovering the disagreement on a full batch.

Where we fit

We hold these figures because we maintain them across the suppliers we broker, and we ask the five questions above on every quote as a matter of course. If you send a specification we will come back with a lead time broken down by phase from each supplier, on one basis, so you can see which quote is genuinely faster rather than which one rounded more optimistically.

We do not manufacture and we hold no inventory, which means we have no reason to tell you a lead time is shorter than it is.

Realistic lead times for cells, tissue and custom devices